Skip to content

Clinical effect of

Clinical effect of

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062754
Enrollment
Unknown
Registered
2022-08-18
Start date
2022-08-18
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

repeated implantation failure

Interventions

Experimental group?control group:"warming yang and resolving turbidity" acupuncture

Sponsors

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
22 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Married women, age >= 22 and = 1 high-quality embryos that planned to be treated with FET and had transplantable cryopreserved blastocysts or the number of cells on day 3 was >= 6 cells 5. Voluntary test, and signed informed consent

Exclusion criteria

Exclusion criteria: 1. Those who receive donor eggs or sperm 2. Other endocrine diseases such as thyroid disease, hyperprolactinemia, insulin resistance, diabetes mellitus, adrenal diseases, etc 3. Combined with uterine lesions that may affect implantation (including uterine malformation, uterine tuberculosis, intrauterine adhesion, submucosal fibroids, endometriosis, adenomyosis, intramural myomas > 4cm) 4. With internal medicine, surgery, psychiatric and other serious primary diseases, acute infectious diseases, body organic diseases, tumor diseases 5. Chromosomal abnormalities in one or both spouses (except chromosomal polymorphism) 6. People with a history of needle-sickness Patients with any of the above conditions will not be included.

Design outcomes

Primary

MeasureTime frame
Embryo implantation rate;

Secondary

MeasureTime frame
Biochemical pregnancy rate;clinical pregnancy rate;Persistent pregnancy rate;HCG day intrauterine thickness;HCG day intrauterine morphology;HCG day intrauterine blood flow branch;hemodynamic index;resistance index;Peak systolic velocity/end diastolic velocity;leukaemia inhibitory factor;HOXA10;Integrin alpha V beta 3;

Countries

China

Contacts

Public ContactBaojuan Wang
xintongmm@163.com13820187330

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026